Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$2.62 +2.0%	$2.50	$1.60 ▼ $17.55	$70.93M	1.65	407,867 shs	9,363 shs
ASRT Assertio	$0.67 +0.7%	$0.66	$0.51 ▼ $1.80	$63.41M	0.29	527,711 shs	29,632 shs
CLSD Clearside Biomedical	$0.83 +0.8%	$0.82	$0.70 ▼ $1.65	$64.81M	2.05	360,061 shs	4,425 shs
HOTH Hoth Therapeutics	$1.38 +3.0%	$1.12	$0.58 ▼ $3.80	$18.23M	0.67	3.71 million shs	48,613 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-4.62%	+3.20%	+6.83%	+15.18%	-82.21%
ASRT Assertio	-3.70%	-4.10%	+4.49%	+6.31%	-57.12%
CLSD Clearside Biomedical	-0.19%	-0.65%	+3.43%	-4.87%	-33.27%
HOTH Hoth Therapeutics	-6.29%	+3.08%	+3.08%	+73.17%	+52.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	2.1546 of 5 stars	3.3	3.0	0.0	0.0	1.3
ASRT Assertio	1.8537 of 5 stars	3.5	0.0	2.2	0.8	1.3
CLSD Clearside Biomedical	2.0174 of 5 stars	3.5	3.0	3.1	0.0	0.0
HOTH Hoth Therapeutics	3.2938 of 5 stars	3.6	5.0	3.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	224.30% Upside
ASRT Assertio	3.00	Buy	$2.75	313.53% Upside
CLSD Clearside Biomedical	3.00	Buy	$4.75	469.54% Upside
HOTH Hoth Therapeutics	3.25	Buy	$4.00	189.86% Upside

Current Analyst Ratings Breakdown

Latest HOTH, ANRO, CLSD, and ASRT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/15/2025	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
5/13/2025	ASRT Assertio	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$5.62 per share	N/A
ASRT Assertio	$119.00M	0.54	$0.05 per share	13.97	$1.27 per share	0.52
CLSD Clearside Biomedical	$3.76M	17.22	N/A	N/A	($0.51) per share	-1.64
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$61.43M	-$2.34	N/A	N/A	N/A	N/A	-39.35%	-33.86%	8/12/2025 (Estimated)
ASRT Assertio	-$21.58M	-$0.32	N/A	22.17	N/A	-25.72%	-24.87%	-10.87%	8/6/2025 (Estimated)
CLSD Clearside Biomedical	-$34.35M	-$0.41	N/A	N/A	N/A	-818.57%	N/A	-114.23%	8/11/2025 (Estimated)
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)

Latest HOTH, ANRO, CLSD, and ASRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	N/A	N/A	N/A	$0.50 million	N/A
8/8/2025	N/A	HOTH Hoth Therapeutics	-$0.27	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ASRT Assertio	-$0.06	N/A	N/A	N/A	$27.86 million	N/A
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	-$0.53	+$0.06	-$0.56	N/A	N/A
5/12/2025	Q1 2025	ASRT Assertio	-$0.06	-$0.14	-$0.08	-$0.14	$27.52 million	$26.49 million
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.15	22.53	22.53
ASRT Assertio	0.36	1.66	1.35
CLSD Clearside Biomedical	N/A	3.19	3.19
HOTH Hoth Therapeutics	N/A	15.09	15.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
ASRT Assertio	48.96%
CLSD Clearside Biomedical	18.75%
HOTH Hoth Therapeutics	7.08%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	N/A
ASRT Assertio	4.00%
CLSD Clearside Biomedical	6.20%
HOTH Hoth Therapeutics	6.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.07 million	N/A	N/A
ASRT Assertio	20	95.78 million	91.95 million	Optionable
CLSD Clearside Biomedical	30	77.71 million	72.89 million	Optionable
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable

HOTH, ANRO, CLSD, and ASRT Headlines

Recent News About These Companies

Hoth Therapeutics (NASDAQ:HOTH) Upgraded to Hold at Wall Street Zen

July 6, 2025 | americanbankingnews.com

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ:

June 26, 2025 | ktla.comK

Silo Pharma Enters into Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

June 26, 2025 | jcnnewswire.comJ

HOTH THERAPEUTICS INC - FinanzNachrichten.de

June 26, 2025 | finanznachrichten.de

Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study

June 26, 2025 | finance.yahoo.com

Silo Pharma, Hoth Therapeutics Enter LOI to Develop Obesity Treatment

June 26, 2025 | contractpharma.comC

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

June 25, 2025 | prnewswire.com

Hoth Therapeutics stock rises after positive Phase 2a trial results

June 24, 2025 | investing.com

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

June 24, 2025 | prnewswire.com

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

June 23, 2025 | prnewswire.com

Hoth Therapeutics, Inc.: Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity ...

June 20, 2025 | finanznachrichten.de

Hoth Therapeutics, Inc.: Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

June 19, 2025 | finanznachrichten.de

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

June 18, 2025 | prnewswire.com

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

June 18, 2025 | prnewswire.com

Hoth Therapeutics to Attend 2025 BIO International Convention

June 16, 2025 | prnewswire.com

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

June 12, 2025 | prnewswire.com

Hoth Therapeutics, Inc.: Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

June 11, 2025 | finanznachrichten.de

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

June 11, 2025 | prnewswire.com

Empire Or Rebellion? Choose Your Side In Star Wars: Battle of Hoth

June 9, 2025 | beastsofwar.comB

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

June 5, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOTH, ANRO, CLSD, and ASRT Company Descriptions

Alto Neuroscience NYSE:ANRO

$2.62 +0.05 (+1.98%)

As of 10:17 AM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Assertio NASDAQ:ASRT

$0.66 +0.00 (+0.71%)

As of 10:18 AM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Clearside Biomedical NASDAQ:CLSD

$0.83 +0.01 (+0.80%)

As of 10:14 AM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Hoth Therapeutics NASDAQ:HOTH

$1.38 +0.04 (+2.99%)

As of 10:18 AM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time